BR112019001607A2 - inibidores macrocíclicos de quinases - Google Patents

inibidores macrocíclicos de quinases

Info

Publication number
BR112019001607A2
BR112019001607A2 BR112019001607-4A BR112019001607A BR112019001607A2 BR 112019001607 A2 BR112019001607 A2 BR 112019001607A2 BR 112019001607 A BR112019001607 A BR 112019001607A BR 112019001607 A2 BR112019001607 A2 BR 112019001607A2
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
macrocyclic kinase
macrocyclic
methods
present disclosure
Prior art date
Application number
BR112019001607-4A
Other languages
English (en)
Inventor
Jean Cui Jingrong
Li Yishan
W. Rogers Evan
Zhai Dayong
Ung Jane
Original Assignee
Tp Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tp Therapeutics, Inc. filed Critical Tp Therapeutics, Inc.
Publication of BR112019001607A2 publication Critical patent/BR112019001607A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

a presente descrição refere-se a certos inibidores de quinase macrocíclicos, composições farmacêuticas contendo os mesmos e métodos de uso dos mesmos para tratar doenças.
BR112019001607-4A 2016-07-28 2017-07-27 inibidores macrocíclicos de quinases BR112019001607A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662367886P 2016-07-28 2016-07-28
US62/367,886 2016-07-28
PCT/US2017/044214 WO2018022911A1 (en) 2016-07-28 2017-07-27 Macrocycle kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112019001607A2 true BR112019001607A2 (pt) 2019-04-30

Family

ID=61016718

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019001607-4A BR112019001607A2 (pt) 2016-07-28 2017-07-27 inibidores macrocíclicos de quinases

Country Status (15)

Country Link
US (1) US10689400B2 (pt)
EP (1) EP3490564A4 (pt)
JP (1) JP2019527230A (pt)
KR (1) KR20190034225A (pt)
CN (1) CN109715165A (pt)
AU (1) AU2017302019A1 (pt)
BR (1) BR112019001607A2 (pt)
CA (1) CA3031100A1 (pt)
IL (1) IL264395A (pt)
MX (1) MX2019001125A (pt)
RU (1) RU2019105587A (pt)
SG (1) SG11201900163PA (pt)
TW (1) TW201815799A (pt)
WO (1) WO2018022911A1 (pt)
ZA (1) ZA201901034B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031863B1 (ru) 2014-01-24 2019-03-29 ТиПи ТЕРАПЬЮТИКС, ИНК. Диарильные макроциклы в качестве модуляторов протеинкиназ
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
EP3325488B1 (en) 2015-07-21 2020-06-24 Turning Point Therapeutics, Inc. Chiral diaryl macrocycle and use thereof in the treatment of cancer
TW201815799A (zh) 2016-07-28 2018-05-01 美商Ｔｐ生物醫藥公司 巨環激酶抑制劑
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
BR112020001695A2 (pt) * 2017-07-28 2020-07-21 Turning Point Therapeutics, Inc. compostos macrocíclicos e usos dos mesmos
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
RS63787B1 (sr) 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti
EP3774812A4 (en) 2018-03-28 2021-12-15 Fochon Pharmaceuticals, Ltd. MACROCYCLIC COMPOUNDS AS TRK CINEMA INHIBITORS
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
CA3117200A1 (en) 2018-10-22 2020-04-30 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
CN113727984B (zh) * 2019-05-21 2024-03-15 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
CN112110938B (zh) * 2019-06-21 2021-11-09 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
WO2021027503A1 (zh) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 三环类化合物、其制备方法、中间体及应用
EP4114530A4 (en) * 2020-03-02 2024-04-17 Turning Point Therapeutics Inc THERAPEUTIC USES OF MACROCYCLIC COMPOUNDS
CN113754682B (zh) * 2020-06-04 2023-01-06 赛诺哈勃药业（成都）有限公司 具有大环结构的化合物及其用途
WO2022171139A1 (zh) * 2021-02-10 2022-08-18 北京国鸿生物医药科技有限公司 一种巨环化合物、药物组合物以及其用途
CN113354548A (zh) * 2021-04-12 2021-09-07 常熟耐素生物材料科技有限公司 一种基于六亚甲基四胺的植物多烯酚醛胺环氧固化剂及其制备方法
WO2023078267A1 (zh) * 2021-11-02 2023-05-11 赛诺哈勃药业（成都）有限公司 作为蛋白激酶调节剂的含氨基大环化合物
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3298885B2 (ja) 1993-03-25 2002-07-08 ファルマシア・アンド・アップジョン・カンパニー ドーパミン作働性活性を有するインドールテトラリン類
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
EA201100450A1 (ru) 2008-09-08 2011-10-31 Мерк Патент Гмбх Макроциклические пирамидины в качестве ингибиторов протеинкиназы
CA2952692C (en) 2008-09-22 2020-04-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds
TWI458729B (zh) 2008-10-22 2014-11-01 Array Biopharma Inc 作為ＴＲＫ激酶抑制劑之經取代吡唑并〔１，５－ａ〕嘧啶化合物
EP2962566A1 (en) 2008-10-31 2016-01-06 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
CR20170098A (es) 2010-05-20 2017-07-17 Array Biopharma Inc Compuestos macrociclicos como inhibidores de quinasa trk
US8757434B2 (en) * 2010-07-01 2014-06-24 The Coca-Cola Company Merchandiser
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
RU2598840C2 (ru) * 2011-05-19 2016-09-27 Фундасион Сентро Насиональ Де Инвестигасионес Онколохикас Карлос Iii Новые соединения
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
RU2014110399A (ru) 2011-08-19 2015-09-27 Мерк Шарп И Доум Корп. Кристаллические формы вгс протеазного ингибитора
KR20140095477A (ko) * 2011-09-30 2014-08-01 입센 파마 에스.에이.에스 마크로시클릭 lrrk2 키나제 억제제
BR112014007622A2 (pt) 2011-09-30 2017-04-04 Oncodesign Sa inibidores de flt3 cinase macrocíclicos
NZ627900A (en) 2012-03-06 2016-08-26 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
EP2822559B1 (en) 2012-03-09 2018-05-02 Lexicon Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof
CA2866143C (en) 2012-03-09 2020-08-04 Lexicon Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
KR20150133765A (ko) * 2013-03-15 2015-11-30 온코디자인 에스.에이. 거대고리 rip2 키나제 억제제
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
EA031863B1 (ru) * 2014-01-24 2019-03-29 ТиПи ТЕРАПЬЮТИКС, ИНК. Диарильные макроциклы в качестве модуляторов протеинкиназ
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
JP6917974B2 (ja) 2015-07-06 2021-08-11 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ジアリール大環状多形
EP3325488B1 (en) 2015-07-21 2020-06-24 Turning Point Therapeutics, Inc. Chiral diaryl macrocycle and use thereof in the treatment of cancer
TW201815799A (zh) 2016-07-28 2018-05-01 美商Ｔｐ生物醫藥公司 巨環激酶抑制劑
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
BR112020001695A2 (pt) 2017-07-28 2020-07-21 Turning Point Therapeutics, Inc. compostos macrocíclicos e usos dos mesmos

Also Published As

Publication number Publication date
RU2019105587A3 (pt) 2020-11-18
AU2017302019A1 (en) 2019-02-07
SG11201900163PA (en) 2019-02-27
ZA201901034B (en) 2021-06-30
WO2018022911A1 (en) 2018-02-01
EP3490564A1 (en) 2019-06-05
MX2019001125A (es) 2019-06-12
KR20190034225A (ko) 2019-04-01
JP2019527230A (ja) 2019-09-26
US20190169208A1 (en) 2019-06-06
RU2019105587A (ru) 2020-08-28
US10689400B2 (en) 2020-06-23
EP3490564A4 (en) 2020-02-26
CA3031100A1 (en) 2018-02-01
IL264395A (en) 2019-02-28
TW201815799A (zh) 2018-05-01
CN109715165A (zh) 2019-05-03

Similar Documents

Publication Publication Date Title
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112018067408A2 (pt) formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
CO2017002532A2 (es) Indazoles sustituidos con bencilo como inhibidores de bub1
ECSP17003553A (es) Compuestos de heteroarilo para la inhibición de cinasa
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
CL2016001895A1 (es) Compuestos
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
EA201691582A1 (ru) Новые фармацевтические препараты
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
BR112015023760A2 (pt) compostos e composições terapêuticas
BR112016007467A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
BR112017008714A2 (pt) inibidores de bromodomínio
BR112016004245A2 (pt) moduladores de sez6 e métodos de uso
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TURNING POINT THERAPEUTICS, INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements